Skip to Main Content
Contribute Try STAT+ Today

Rise and shine. Another busy day is on the way. And it appears to be yet another cold one, too. But it is wintertime, after all. To keep warm, yes, we are brewing that mandatory cup of stimulation — we are back to Southern Pecan for those keeping track — and invite you to join us. Once again, we are happy to remind you that a prescription is not required. But now, on with the show. As always, we have assembled a menu of tidbits to get you going. Good luck, today, and do stay in touch. …

Biogen (BIIB) chief executive officer Michel Vounatsos acknowledged Monday that the company was “wrong” to price its Alzheimer’s disease treatment at $56,000 a year, but added that its decision to later slash the cost nearly in half was “courageous,” STAT reports. Speaking virtually at the J.P. Morgan Healthcare Conference, Vounatsos defended the initial price for the drug, known as Aduhelm, as “evidence-based,” and argued “this is a price that eventually we could defend.” But he acknowledged that the widespread negative reaction among physicians, patients, and policymakers proved Biogen was “wrong.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment